A Study Evaluating INIPARIB in Combination With Chemotherapy to Treat Triple Negative Breast Cancer Brain Metastasis
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Estrogen Receptor Negative (ER-Negative) Breast Cancer|Progesterone Receptor Negative (PR-Negative) Breast Cancer|Human Epidermal Growth Factor Receptor 2 Negative (HER2-Negative) Breast Cancer|Brain Metastases
Interventions: DRUG: INIPARIB + irinotecan
Sponsor: Sanofi
Collaborators: UNC Lineberger Comprehensive Cancer Center